share_log

Prelude Therapeutics | 8-K: Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SEC ·  Nov 7, 2024 11:32
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.